AURELIUS completes acquisition of LloydsPharmacy’s parent company, McKesson UK
Luxembourg/London, April 07, 2022 – AURELIUS is pleased to announce that it has successfully closed the acquisition of McKesson UK. McKesson UK is the parent company of a number of market leading healthcare businesses including LloydsPharmacy, John Bell & Croyden and AAH Pharmaceuticals. This landmark deal marks the fifth completed transaction in less than a year for AURELIUS European Opportunities IV, controlling a 70 % stake and its Co-Investor AURELIUS Equity Opportunities SE & Co. KGaA (ISIN: DE000A0JK2A8), controlling the remaining 30 %.
McKesson UK comprises four divisions and holds a substantial market share across each vertical: retail, digital, homecare and wholesale. McKesson UK’s success has been underpinned by its strong LloydsPharmacy brand, its loyal customer base and its leading commercial footprint across wholesale pharmaceuticals. Over recent years, the company has benefited from the introduction of additional services delivered across its more than 1,300 pharmacies, a growing digital offering and the ability to support the increasing trend of primary care being delivered to patients in their home.
AURELIUS will ensure a smooth transition as McKesson UK separates from its former US-based parent company, McKesson Corporation. Furthermore, AURELIUS will seek to leverage McKesson UK’s established market positions to maximise the opportunities available within each division.
AURELIUS was advised by Rothschild & Co. (Corporate Finance), PwC and FRP (Financial), Interpath (Tax), Mayer Brown and DLA (Legal), Cardano (Pensions), Kearney (IT) and Mansfield (Commercial).